Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men.

Karien C M Gosens Sjoerd H Van der Burg Marij J P Welters Sanne Boekestijn Nikki M Loof Wim G V Quint Carel J M van Noesel Allard C van der Wal Olivier Richel Wilhelmus J T A Krebber Cornelis J M Melief Henry John Christiaan de Vries Jan M Prins

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The highest dose level is safe, immunogenic and associated with clinical responses to HPV16-induced lesions. However, as the majority of HGAIN is caused by the other HPV types, further studies should aim at pan-HPV vaccination to prevent or treat HGAIN.

Keyphrases

high grade
antiretroviral therapy
hiv infected
hiv positive
human immunodeficiency virus
hepatitis c virus
high glucose
hiv testing
hiv aids
men who have sex with men
cervical cancer screening
oxidative stress
south africa
stress induced